Despite the promise of advanced targeting mechanisms, several challenges remain:
1. Stability: Ensuring that nanoparticles remain stable in the bloodstream without premature release of the drug. 2. Immunogenicity: Reducing the immune response against nanoparticles to avoid rapid clearance. 3. Scaling Up: Manufacturing nanoparticles consistently and at a scale suitable for clinical use. 4. Regulatory Hurdles: Meeting stringent safety and efficacy standards set by regulatory bodies.
